131 related articles for article (PubMed ID: 28392461)
41. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
42. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
43. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Moores SL; Chiu ML; Bushey BS; Chevalier K; Luistro L; Dorn K; Brezski RJ; Haytko P; Kelly T; Wu SJ; Martin PL; Neijssen J; Parren PW; Schuurman J; Attar RM; Laquerre S; Lorenzi MV; Anderson GM
Cancer Res; 2016 Jul; 76(13):3942-53. PubMed ID: 27216193
[TBL] [Abstract][Full Text] [Related]
44. An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer.
Zhong G; Xu Z; Yang R; Zhang S; Li L; Wu M; Liu H; Zhen Y
J Cancer; 2018; 9(4):674-682. PubMed ID: 29556325
[TBL] [Abstract][Full Text] [Related]
45. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
[TBL] [Abstract][Full Text] [Related]
46. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
47. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
48. FNC inhibits non-small cell lung cancer by activating the mitochondrial apoptosis pathway.
Jing X; Niu S; Liang Y; Chen H; Wang N; Peng Y; Ma F; Yue W; Wang Q; Chang J; Zhang Y; Zhang Y
Genes Genomics; 2022 Jan; 44(1):123-131. PubMed ID: 34697761
[TBL] [Abstract][Full Text] [Related]
49. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.
Jia Y; Juarez J; Li J; Manuia M; Niederst MJ; Tompkins C; Timple N; Vaillancourt MT; Pferdekamper AC; Lockerman EL; Li C; Anderson J; Costa C; Liao D; Murphy E; DiDonato M; Bursulaya B; Lelais G; Barretina J; McNeill M; Epple R; Marsilje TH; Pathan N; Engelman JA; Michellys PY; McNamara P; Harris J; Bender S; Kasibhatla S
Cancer Res; 2016 Mar; 76(6):1591-602. PubMed ID: 26825170
[TBL] [Abstract][Full Text] [Related]
50. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
52. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
53. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
54. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
[TBL] [Abstract][Full Text] [Related]
55. Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo.
Chen Z; Huang X; Yang H; Ding W; Gao L; Ye Z; Zhang Y; Yu Y; Lou Y
Chem Biol Interact; 2011 Jan; 189(1-2):90-9. PubMed ID: 21075094
[TBL] [Abstract][Full Text] [Related]
56. Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.
Zhong GS; Wu MN; Guo XF; Xu ZS; Zhang SH; Zhen YS
Oncol Lett; 2013 Apr; 5(4):1183-1188. PubMed ID: 23599760
[TBL] [Abstract][Full Text] [Related]
57. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
[TBL] [Abstract][Full Text] [Related]
58. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
